Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.